No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NKTR Nektar Therapeutics
- 1.4800
- +0.0200+1.37%
Close Jul 23 16:00 ET
272.35MMarket Cap-1626P/E (TTM)
1.5000High1.4300Low724.97KVolume1.4500Open1.4600Pre Close1.07MTurnover0.44%Turnover RatioLossP/E (Static)184.02MShares1.928052wk High2.15P/B242.16MFloat Cap0.412652wk Low--Dividend TTM163.62MShs Float111.3600Historical High--Div YieldTTM4.80%Amplitude0.4126Historical Low1.4720Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
There's Reason For Concern Over Nektar Therapeutics' (NASDAQ:NKTR) Massive 26% Price Jump
Nektar Therapeutics' (NASDAQ:NKTR) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 13% Over the Past Week
Rodman & Renshaw Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $2
Oppenheimer Maintains Nektar Therapeutics(NKTR.US) With Hold Rating
Nektar Therapeutics(NKTR.US) Director Sells US$23,400 in Common Stock
Express News | Nektar Therapeutics - Ind-Enabling Studies Underway for Nktr-0165 With First-in-Human Studies Planned in First Half of 2025
Comments
$Nektar Therapeutics(NKTR.US$
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associ...
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associ...
$Nektar Therapeutics(NKTR.US$ why such a drop today?
$Nektar Therapeutics(NKTR.US$ raise ur hand if u bought this above 50dollars 😂😂😂
1
1
$Nektar Therapeutics(NKTR.US$ Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq
1
$Nektar Therapeutics(NKTR.US$ • Nektar Therapeutics has regained full rights to its drug candidate REZPEG and is advancing Phase 2b studies for atopic dermatitis and alopecia areata.
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg